3.23
+4.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About KORU Medical Systems
From its filings with the US Securities and Exchange Commission
KORU Medical Systems is based in Mahwah, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker KRMD. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $41.1m and a net loss of $2.6m. At that date it held total assets of $28.2m and shareholders' equity of $17.0m. By region, UNITED STATES accounted for 73.5%, followed by Non-US [Member] at 26.5%.
Increasing diagnoses of Primary Immunodeficiency Diseases (PIDD), which frequently require immunoglobulin (Ig) treatment.
Expansion of on-label SCIg indications, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Secondary Immunodeficiency Diseases (SIDD), and additional conditions currently in clinical development.
Growth in SCIg treatment options; KORU is well positioned to lead the global transition to prefilled syringe delivery across major drug brands, with a focus on improving the SCIg patient experience.
Ongoing biopharmaceutical investment in SCIg therapies, including prefilled syringe formats designed to enhance ease of use and expand patient eligibility for SCIg treatment.
Increasing availability of donated plasma, which supports the growing global supply of Ig medications.
Patient preference and cost-effectiveness of at-home SCIg therapy, which offers a favorable side effect profile and health economic advantages compared to intravenous Ig (IVIg) treatment.
FREEDOM System. The needle sets are available in 26- and 24-gauge sizes and feature unique design elements specific to subcutaneous self-administration.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 27 Oct 1993
- Employees
- 73
- Website
- repro-med.com ↗
- Head office
- 100 CORPORATE DRIVE, MAHWAH, NJ, 07430
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. R. John FletcherIndependent Chairman of the Board$102,335
- Ms. Linda TharbyPresident, Chief Executive Officer$725,169
- Ms. Karen FisherChief Financial Officer, Secretary, Treasurer$297,994
- Mr. Manuel MarquesChief Operating Officer$260,249
- Mr. Brian CaseChief Technology Officer
- Mr. James BeckIndependent Director, since 2018$397,714
- Dr. Donna FrenchIndependent Director$40,796
- Mr. Joseph MankoIndependent Director$89,856
- Mr. Shahriar MatinIndependent Director$71,133
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 32
- Social
- 19
- Governance
- 53
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Repro Med Systems Inc (RMS) benefits from several strengths that contribute to its success in the market. One of its key strengths is its proprietary product portfolio, which includes the innovative Freedom infusion system. This product offers unique advantages such as portability, disposability, and ease of use, giving RMS a competitive edge.
- Another strength of RMS is its strong market presence and established customer base. The company has built solid relationships with healthcare providers and distributors, which helps in generating recurring revenue and ensures a steady stream of sales.
Weaknesses
- Despite its strengths, RMS also faces certain weaknesses that need to be addressed. One weakness is its dependency on a limited number of key suppliers for critical components of its products. Any disruptions in the supply chain can have a significant impact on production and delivery timelines.
- Additionally, RMS has a relatively small product portfolio compared to some of its competitors. This narrow product range limits the company's ability to cater to diverse customer needs and potentially hinders its market expansion efforts.
Opportunities
- The healthcare industry is experiencing significant growth, presenting ample opportunities for RMS. The increasing prevalence of chronic diseases and the rising elderly population create a higher demand for home-based medical devices, such as RMS' infusion systems. By capitalizing on this trend, RMS can expand its customer base and increase its market share.
- Another opportunity for RMS lies in the emerging markets, where the demand for medical devices is steadily growing. By strategically targeting these markets and adapting its products to meet local requirements, RMS can tap into new revenue streams and achieve global expansion.
Threats
- RMS faces several threats that could potentially impact its business. One major threat is intense competition from other medical device manufacturers. The healthcare industry is highly competitive, and RMS needs to continuously innovate and differentiate its products to stay ahead of rivals.
- Additionally, regulatory challenges pose a threat to RMS's operations. Compliance with strict regulations and obtaining necessary approvals can be time-consuming and costly. Any delays in obtaining regulatory approvals can hinder product launches and impede market growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.